Drug class
Janus Kinase Inhibitor
Mechanism of action
Janus Kinase Inhibitors [MoA]
General use cases
- Arthritis, Rheumatoid
- moderately to severely active rheumatoid arthritis in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers
- coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)
- severe alopecia areata in adults and pediatric patients 12 years of age and older
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
